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questionnaire regarding symptoms and treatment of AB-SE 
patients. Seven centers responded positively, providing a to-
tal of 13 patients above the age of 16.  Results: AB-SE affects 
mainly women (12/13, 92%) with a variable age at onset (17–
69 years, median: 25 years). The duration of the disease is also 
variable (10 days to 12 years, median: 2 months). Only the 3 
oldest patients died (55–69 years). Most patients were diag-
nosed with anti NMDAR encephalitis (8/13) and had oligo-
clonal bands in the CSF (9/13). No specific treatment regimen 
(antiepileptic, immunomodulatory) was found to be clearly 
superior. Most of the surviving 10 patients (77%) recovered 
completely or nearly so within 2 years of index poststatus. 
 Conclusion: AB-SE is a severe but potentially reversible con-
dition. Long duration does not seem to imply fatal outcome; 
however, age older than 50 years at time of onset appears to 
be a risk factor for death. There was no evidence for an opti-
mal antiepileptic or immunomodulatory treatment. A pro-
spective multicenter study is warranted in order to stratify 
the optimal treatment algorithm, determine clear risk factors 
of unfavorable outcome and long-term prognosis. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: In recent years, an increasing number of auto-
antibodies (AB) have been detected in the CSF and serum of 
patients with new onset epilepsy. Some of these patients de-
velop convulsive or nonconvulsive status epilepticus (AB-
SE), necessitating intensive medical care and administra-
tion of multiple antiepileptic and immunomodulatory treat-
ments of uncertain effectiveness.  Objectives: In this retro-
spective multicenter survey we aimed to determine the 
spectrum of gravity, the duration and the prognosis of the 
disorder. In addition, we sought to identify the antibodies 
associated with this condition, as well as determine whether 
there is a most effective treatment regime.  Methods: 12 Eu-
ropean Neurology University Clinics, with extensive experi-
ence in the treatment of SE patients, were sent a detailed 
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 Introduction 
 In the last few years, an increasing number of auto-
antibodies has been detected in patients with new onset 
epilepsy, leading to the concept of a subgroup of epilepsy 
as an autoimmune disease  [1–3] . Some antibodies (AB) 
like those directed to glutamic acid decarboxylase (GAD-
AB, associated with stiff-person syndrome and epilepsy) 
seem to be of autoimmune origin, others like anti-Hu of 
paraneoplastic, whereas NMDAR-AB can be of either 
origin  [4] . It is hypothesized that some of these antibod-
ies modulate the equilibrium between excitatory and in-
hibitory mechanisms in the central nervous system, ei-
ther by targeting ion channels (e.g. antibodies against
N-methyl- D -aspartate receptor; NMDAR-AB  [5] ) or key 
enzymes (e.g. antibodies against GAD, the enzyme 
which converts glutamic acid into gamma aminobutyric 
acid  [6] ), leading to a gain of excitability or a lack of in-
hibition and consequently resulting in seizures, among 
other symptoms. 
 Some of these patients with AB develop status epilep-
ticus (AB-SE)  [7] , convulsive or nonconvulsive, and
require prolonged intensive care, mechanical ventila-
tion and multiple antiepileptic and immunomodulatory 
treatments  [8, 9] . To date, there are no good data about 
the ultimate outcome of these patients. There is also 
sparse knowledge about the most effective treatments. 
It is therefore important to comprehensively investigate 
the clinical characteristics and course of AB-SE and 
whether there is a uniquely successful treatment regi-
men. 
 Methods  
 We sent a detailed questionnaire to 12 European Neurology 
University Clinics, with extensive experience in the treatment of 
SE. The study was limited to patients older than 16 years. Seven 
centers responded positively (Berne, Lausanne, Zurich, Berlin, 
Bonn, Erlangen, Ulm), providing a total of 13 patients, including 
our 2 patients (Geneva), diagnosed with AB-SE between 2003 and 
2011. 
 We inquired about patient characteristics, clinical features, 
history of neoplasia or autoimmune disease, duration of SE ( ta-
ble  1 ), antibodies and paraclinical findings including imaging, 
results of CSF and ictal and interictal EEG ( table 2 ) and adminis-
tered treatments and outcome ( table 3 ).
 There is no universally accepted definition of nonconvulsive 
status epilepticus (NCSE); however, all our patients showed ab-
normal, focal, or multifocal or generalized rhythmic activity, with 
evolution in frequency, morphology and field (except in 1 patient 
where judgment was based purely on the clinical picture).
 Results 
 Clinical Findings 
 Patients were aged from 17 to 69 years; the mean age 
was 32.5 years (17–69 years, median 25 years). There was 
a high female-male ratio (12/13; 92%). 
 One patient presented prodromal, unspecific symp-
toms, such as fatigue or headache before the occurrence 
of status epilepticus (SE), neuropsychiatric symptoms in-
cluding behavioral changes, memory loss, agitation and 
psychosis, or isolated simple, complex partial or general-
ized epileptic seizures were found in 12 patients. Alto-
gether, 12 of 13 had more or less significant clinical symp-
toms before AB-SE occurred. 
 When hospitalized for SE, 3 patients were found to 
have an underlying neoplastic disease (23%: 2 ovarian 
teratoma and 1 small cell lung cancer); whereas in 2 oth-
er patients an ovarian teratoma was diagnosed only later, 
i.e. 1 and 2 years, respectively, after complete recovery 
(total of patients with tumor 38%). One patient suffered 
from steroid-responsive encephalitis associated with thy-
roiditis (Hashimoto).
 The latencies between the first symptoms and the on-
set of status epilepticus varied from 0 to 11 months. In 
7/13 patients (53%), SE was present within the first week 
of symptoms. In the other half (47%), the delay between 
onset and SE was between 1 week and 11 months (mean 
3.3 months, median 1 month).
 Duration of SE varied considerably from 2 h to 12 
years, in 3 cases less than a month (2 h, 10 and 18 days, 
respectively), in 1 case 12 years (patient 5), but in the ma-
jority (9 of 13) SE lasted between 1 and 4 months. Nine 
patients needed pharmacological coma induction and 
mechanical ventilation, independently of duration or 
type of AB.
 The majority of our patients (70%) had either complex 
partial (7/13), or generalized tonic-clonic seizures (5/13). 
Only 1 patient presented with simple partial seizures.
 Paraclinical Findings 
 Serum 
Serum antibodies against NMDA receptor were most 
frequently associated with SE, found in 8 of 13 patients 
(61%; patients 1, 2, 5, 7, 8, 9, 10 and 12). Except in patient 
8, where it was not specifically tested, all patients with 
these serum antibodies also had NMDAR-AB in the ce-
rebrospinal fluid. 
 Antibodies against GAD were found in 1 patient (No. 
11, also positive in the CSF), and against hippocampal 
neuropil without further specification of the reactivity 
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(negative for all known antigenic specificities, No. 13) in 
another patient, whereas in 2 patients (Nos. 3 and 6) the 
testing for any of these serum antibodies was negative. 
However, in these 2 patients, oligoclonal bands in the CSF 
indicated autoimmune origin. Patient 6 had none of these 
serum antibodies, but antibodies against GluR3 in the 
CSF were present. In patient 4 Ri-AB was found in the 
serum, but not in the CSF. 
 Cerebrospinal Fluid 
Oligoclonal bands were found in 9/13 patients (69%), 
including NMDAR-AB and non-NMDAR-AB patients. 
White blood cell counts (WBC) were also elevated in 
most patients (in 11 of 13 patients; 85%), ranging from 6 
to 134 million/l. Only patient 6 with anti-GluR3 and pa-
tient 11 with GAD-AB had normal WBC. Abnormally 
elevated CSF protein levels were found in 4 patients (30%), 
Table 1. P atients and clinical features
Pa-
tient
No.
Refer-
ence
center
Gen-
der
Age at 
onset
years
First symptoms Neoplasia or 
other diseases
Beginning of 
epilepsy after 
onset of first 
symptoms
Type of 
epilepsy
Duration
of status
epilepticus
Intuba-
tion
1 Geneva M 58 headache, disinhibition, 
aggressivity, short term 
memory loss
none 6 months facial and upper 
limbs myoclonus 
(CP)
4 months yes
2 Geneva F 22 dizziness, disorientation, 
amnesia, agitation,
epileptic seizure
ovarian teratoma 
discovered 1 year
after full recovery
1 week NCSE 2 months yes
3 Berne F 55 loss of energy,
restlessness, short term
memory loss
none 11 months GTCS 10 days yes
4 Lausanne F 69 generalized clonic and
CP seizures, progressive
obtundation
small cell lung 
cancer
0 months GC and CP 
seizures
26 days
(1 month)
yes
5 Lausanne F 25 fatigue, somnolence,
dysphasia
none 3 weeks GC and CP 
seizures
3 months no
6 Lausanne F 28 SP seizures none 0 months SP seizures 12 years yes
7 Zurich F 37 psychosis, disorientation, 
agitation, dysphagia,
dysarthria
ovarian teratoma 0 months NCSE 4 months yes
8 Zurich F 36 psychosis, depression,
insomnia, dyslexia
none 0 months NCSE 4 months yes
9 Berlin F 19 headache, epileptic 
seizure, disorientation, 
anxiety, irritability
ovarian teratoma 0 months GTCS 2 h no
10 Bonn F 17 GTCS none 0 months GTCS 18 days no
11 Erlangen F 21 dystonia Hashimoto 1 month CP seizures 2 and 
3 months
yes
12 Ulm F 17 psychosis, agitation,
seizures, amnesia
none 1 month GTCS 5 weeks yes
13 Ulm F 19 psychosis, agitation,
seizures, amnesia,
incontinence, mild
dyskinesia
ovarian teratoma 
discovered 2 years 
after full recovery 
0 months GTCS intermittent 
for a few
weeks
no
NCSE = Nonconvulsive status epilepticus; GTCS = generalized tonic-clonic seizures; GC = generalized clonic; CP = complex partial; SP = simple 
partial.
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Table 2.  Antibodies and paraclinical findings
Pa-
tient 
No.
AB in serum AB in CSF Brain MRI FDG-PET CSF Interictal EEG Ictal EEG
1 NMDAR-AB NMDAR-AB normal, then diffuse 
atrophy
severe parieto-
temporo-occipital
and basal ganglia 
hypometabolism 
WBC: 100;
prot: 1 g/l;
OB: positive
(type 2)
continuous 
monomorph theta, 
areactive
NCSE (left temporal, 
right frontal)
2 NMDAR-AB NMDAR-AB normal WBC: 134;
prot: 0.37 g/l;
OB: positive
(type 2)
diffuse polymorph 
delta slowing
rhythmic diffuse 
monomorph delta 
slowing
3 no AB detected no AB
detected
normal, then T2 
hyperintensity in 
bilateral hippocampus
WBC: 15;
prot: 1.6 g/l;
OB: positive
(type 2)
severe general 
slowing
continuous frontal sharp 
slow waves
4 Ri-AB (1/1,280) no AB
detected
multifocal T2 
hyperintensity
WBC: 6;
prot: 0.68 g/l;
OB: positive
diffuse theta-delta, 
irregular slowing
multifocal, bilaterally 
independent seizures
5 NMDAR-AB NMDAR-AB normal, then minimal 
diffuse atrophy
WBC: 27;
prot: 0.37 g/l;
OB: positive
diffuse theta-delta 
slowing
rhythmic anterior delta, 
waxing and waning
6 no
AB detected
anti-GLUR3 progressive, focal right 
parietal atrophy
striatal 
hypermetabolism
normal, no OB right hemispheric 
spikes, multifocal, 
on a moderately 
slow background 
R>L
right hemispheric spikes, 
multifocal, on a 
moderately slow 
background R>L
7 NMDAR-AB NMDAR-AB normal (DVA frontal 
sup. gyrus)
bifrontal and
bithalamic 
hypermetabolism
WBC: 37;
prot: 0.48 g/l;
OB: positive
continuous 
monomorph delta, 
areactive
multifocal NCSE, 
initially bitemporal 
independent, later 
bifrontal
8 NMDAR-AB not done normal, repeatedly hypometabolism 
bioccipital and in
motor cortex bilateral, 
later normalized
WBC: 79;
prot: 0.61 g/l;
OB positive
continuous theta/
delta, areactive
NCSE bifrontotemporal, 
predominant delta 
rhythms
9 NMDAR-AB NMDAR-AB normal, then subtle 
grey matter 
enhancement in 
medial temporal lobes 
and gyrus cinguli
WBC: 39;
prot: 0,39 g/l;
OB: positive
marked slowing 
and epileptic 
activity 
(generalized)
not performed
10 NMDAR-AB NMDAR-AB status related, later on 
regressive bilateral 
cortical signal increase
WBC: 40;
prot: 0.31 g/l;
OB: positive
diffuse theta 
slowing
right hemispheric status
11 GAD-AB anti-GAD initially normal, then 
bitemporal 
hyperintensive lesion
WBC: 2;
prot: normal,
lactate: 2.2 mmol/l
alpha EEG theta, ETPs
12 NMDAR-AB NMDAR-AB normal, repeatedly WBC: 80;
OB: negative
all else negative
irregular theta to 
delta, no ETPs
bifrontal and generalized
13 unclassified AB 
against hippo-
campal neuropil
not done normal, repeatedly WBC: 40;
OB: negative
all else negative
irregular theta to 
delta, no ETPs
bifrontal and generalized
GLUR3-AB = Antiglutamate receptor 3-AB; GAD-AB = glutamic acid decarboxylase-AB; Ri-AB = antineuronal nuclear autoantibody type 2-AB (i.e. 
ANNA-2); DVA = developmental venous anomaly; ETPs = epilepsy-typical potentials; OB = oligoclonal bands; WBC = white blood cells (normal: 0–3).
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independent of the type of AB. Overall, 4 patients had no 
oligoclonal bands (Nos. 6, 11, 12 and 13).
 EEG 
Interictal EEG findings generally showed theta or del-
ta slowing (12 of 13 patients). Only patient 11 with GAD-
AB had a normal interictal EEG. Given that patients were 
in SE, ictal recordings were obtained in all but 1 patient 
(No. 9). In this patient (NMDAR-AB), no ictal EEG was 
obtained due to the short duration of SE. In the remain-
ing, ictal EEG revealed frontal or fronto-temporal seizure 
onset in 7 patients (54%, Nos. 1, 3, 5, 6, 10, 12 and 13), 
multifocal in 1 (No. 4), and nonconvulsive epileptic status 
in 3 patients (Nos. 2, 7 and 8, all NMDAR-AB). Patient 11 
(GAD-AB) showed generalized slowing with epilepti-
form discharges ( fig. 1 ). 
 Brain Imaging 
MRI was initially normal in 10 patients (77%), and re-
mained normal in 5 (patients 2, 7, 8, 12 and 13). Cortical, 
Table 3. T reatments and outcome
Pa-
tient 
No.
Inefficient AED Efficient AED Steroids
i.v.
PE IvIg CPM RTM Outcome
1 LEV + PB + VPA none + + + + + death
2 LEV + VPA + CLP + PRO none + + + – + nearly restitutio ad
integrum (mild dysexe-
cutive disorders)
3 LEV, LTG, VPA none – – – – – death
4 CLZ, LEV, LZP, PHT, TPM, THP none + – – – – death
5 LEV, CBZ, LZP, TPM, THP, 
MDZ, KTM, LCS
PRO + PB + PGB + PHT + + + – – nearly restitutio ad
integrum (mild memory 
dysfunction)
6 PB, CBZ, VPA, VGV, PHT, TPM, 
GBP, PRO
PGB + LTG + LEV + 
CLZ + VNS
+ – – – – markedly reduced seizure 
intensity (after VNS)
7 PHT, VPA, MDZ, THP, LTG, 
LEV, TPM, CLB
none + – + – – nearly restitutio ad 
 integrum
8 VPA, LZP, MDZ, PRO, PHT, PB, 
CLB, TPM, LEV, THP, FBM
none + + + + – severe deficits 
(cognitive, physical, 
 remains dependent)
9 LEV, DZP LZP + PRM + – – – – restitutio ad integrum
10 PHT + LEV, VPA + CLB GBP + PB + PHT + VPA + – – – – nearly restitutio ad
integrum
11 PHT, VPA CLP + GBP + LEV + 
LZP + PRM
– + + + – hearing impairment, no 
cognitive deficits
12 LEV, PHT, TPM, VPA PB (partially) + – – – – restitutio ad integrum 
(after 2 years)
13 LZP, LEV, PHT none – – – – – restitutio ad integrum 
(after 1 year)
C BZ = Carbamazepine; CLB = clobazam; CLP = clonazepam; 
CLZ = clorazepate; DZP = diazepam; FBM = felbamate; GBP = 
gabapentine; KTM = ketamine; LTG = lamotrigine; LEV = leveti-
racetam; LCS = lacosamide; LZP = lorazepam; MDZ = midazo-
lam; PB = phenobarbital; PHT = phenytoin; PGB = pregabaline; 
PRM = primidone; PRO = propofol; THP = thiopental; TPM = 
topiramate; VGV = vigabatrin; VPA = valproic acid; PE = plasma-
pheresis; IvIg = intravenous immunoglobulin; CPM = cyclophos-
phamide; RTM = rituximab; VNS = vagus nerve stimulation.
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hippocampal and temporal signal increase was found in 
4 (patients 3, 9, 10 and 11). Patients 1 and 5 with initially 
normal MRI showed subsequently diffuse atrophy. In pa-
tient 6 with GluR3-AB, a focal right parietal atrophy ap-
peared after 2 years (histologically confirmed adult Ras-
mussen encephalitis, recently reported  [10] ).
 Cerebral FDG-PET scan was done in 4 patients (all 
with NMDAR-AB) and showed in patient 1 severe bilat-
eral parietotemporo-occipital and basal ganglia hypome-
tabolism, in patient 6 striatal hypermetabolism correlat-
ing with disease course (recently reported  [11] ), in patient 
7 bifrontal and bithalamic hypermetabolism, whereas in 
patient 8 bilateral hypometabolism spared the subcorti-
cal regions and was present in the occipital and motor 
cortex regions.
 Treatments and Response 
 Classic antiepileptic and new-generation antiepileptic 
drugs (AED) individually or in combination have been 
used to control AB-SE, but with poor results. Phenytoin, 
valproic acid and levetiracetam or their combination 
have consistently failed, despite dosages and serum levels 
in the recommended therapeutic range. In 7 patients 
(54%) there was no efficient AED at all, whereas 1 patient 
(No. 9) responded to lorazepam and primidone, 3 pa-
tients improved with a combination of 4 AED (Nos. 5, 6 
and 10), and 1 (No. 11) with 5 AED. 
 Of the 8 patients who recovered completely or nearly 
completely, 3 of them (Nos. 9, 10 and 12, all NMDAR-AB) 
received steroids as the unique immunomodulatory 
treatment. Patient 5 (NMDAR-AB) responded with some 
delay to a combination of steroids, plasma exchange (PE) 
and IvIg, or possibly spontaneously, patient 7 (NMDAR-
AB) to steroids and IvIg, whereas patient 13 (AB hippo-
campal neuropil) improved without any immunomod-
ulatory treatment. Patient 6 (GluR3-AB) received ste-
roids early in her illness, but improved somewhat only 
after VNS was implanted several years later. Patient 8 
(NMDAR-AB) responded to steroids, PE, IvIg and cyclo-
phosphamide. Patient 11 (GAD-AB) did not receive ste-
roids but transiently improved after PE and IvIg, and fi-
nally recovered after cyclophosphamide.
 Outcome  
 Eight patients of 13 (62%) recovered completely or 
nearly completely (Nos. 2, 5, 7 and 9–13), despite a mean 
duration of SE of 50 days (patient 11 remained with a 
hearing impairment but no other neurological or cogni-
tive deficits). Only 2 of the 10 surviving patients remained 
severely disabled (patients 8 and 6 with adult Rasmussen 
encephalitis, but stabilized in his course). Recovery may 
be long and in some patients took more than 1–2 years 
(Nos. 12 and 13). Two patients are of special interest: pa-
tient 2 recovered after AED (with no response) and after 
immunomodulatory therapy; however, with persisting 
NMDAR-AB, an ovarian teratoma was found and oper-
ated only 1 year after full recovery. Patient 13, without 
any immunomodulatory treatment and without any re-
 Fig. 1. EEG samples of SE of patients 1 (NMDAR-AB), 11 (GAD-
AB),  and 13 (unclassified antibody), from top to bottom. 
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sponse to AED; this young female recovered spontane-
ously and completely over 1 year, but an ovarian teratoma 
was discovered and removed only 2 years later.
 Three patients died. Patient 1 (NMDAR-AB) died af-
ter several months of SE despite five different immuno-
modulatory treatments and without an underlying tu-
mor disease. Patient 3, with no specific AB detected 
probably died from brain edema and autonomic dys-
function and the course was fulminant (10 days). Patient 
4 died 26 days after onset (Ri-AB and small cell lung can-
cer) during SE.
 Discussion 
 AB-SE is a rare, heterogeneous condition, and diag-
nosed on the basis of clinical features of encephalitis, 
EEG changes and laboratory results, requiring care in in-
tensive care units (ICU). In our retrospective multicenter 
survey of 13 patients, we identified as potential risk fac-
tors female gender (12 of 13) and serum NMDAR-AB (8 
of 13). The prevalence of autoimmune diseases in women 
is well known and possible explanations are provided in 
a recent review  [12] (e.g. higher CD4+ lymphocytes, en-
hanced cytokine production in the presence of estrogen).
 Pathophysiological mechanisms of epilepsy of auto-
immune origin, or its most extreme form AB-SE, are not 
perfectly understood. In particular, it remains unclear as 
to whether the antibodies are pathogenic themselves or 
simply a marker of another directly pathogenic process. 
In any case, the treating physician aims to shorten that 
process by introducing immunomodulatory treatment. 
 In our patient group, there is no evidence for the best 
first-line treatment. Despite attempts to treat with various 
antiepileptic medications of different and complementary 
pharmacological characteristics, inconclusive outcomes 
have resulted with no evidence for a one most effective 
antiepileptic drug or combination therapy.
 No straightforward picture emerged either regard-
ing the immunomodulatory treatments. Ten patients re-
ceived steroids, which did not help in 5/10. Interestingly, 
PE and IvIg were given in less than 50% of the patients, 
despite a long SE duration in some of them (e.g. patients 
4, 12 and 13). This may indicate a delayed referral to neu-
rologists or immunologists and/or limited awareness of 
AB-SE within the ICU staff, delaying reinforcement of 
therapy. Overall, our study cannot confirm or invalidate 
the hypothesis that early and aggressive immunomodu-
latory treatment (e.g. steroids, PE, IvIg, or their associa-
tion) would change the course of the disease. 
 As shown in previous studies  [13, 14] , the removal of 
an underlying tumor, if possible, is related to better out-
come. However, this view is challenged by our observa-
tion. The condition of 2 patients recovered completely be-
fore the tumor was detected, indicating that even in a 
probable paraneoplastic context, conservative treatment 
may be sufficient.
 AB-SE is a serious condition with high mortality (3 of 
13, 23%). Interestingly, all the patients who died were also 
the oldest of our series (55, 58 and 69 years old). While a 
paraneoplastic origin was found in one of them, there was 
no evidence of an underlying tumor in the other 2 pa-
tients. DeLorenzo et al. [15] noted in 1996 that the ‘The 
prognosis of SE in adults is poorer than in children and 
particularly so in those over 60 years of age’. This differ-
ence was thought to be due to the underlying pathology. 
In the DeLorenzo data most of the older subjects suffered 
from brain anoxia or (larger) acute stroke, i.e. a pathology 
that is per se related to a poorer prognosis. However, sev-
eral other papers underscore that age and etiology are the 
most important independent outcome predictors in SE 
 [16] . It remains to be shown in further studies whether 
age will emerge as an independent risk factor in AB-SE 
or if other factors, such as less aggressive therapy in older 
patients, determine this unfavorable outcome. 
 ABs to intracellular antigens may be associated with 
bad response to immunomodulatory treatment and 
poorer outcome, whereas ABs to extracellular antigens 
are believed to have a better prognosis. Our case series 
does not confirm this hypothesis. Of our 3 patients with 
a fatal outcome, only 1 had AB against an intracellular 
antigen (patient 4, Ri-AB), while another had AB against 
an extracellular antigen (patient 1, NMDAR-AB), and in 
1 patient there was no known AB at all. Furthermore, 1 
patient with a good outcome (patient 11) had an AB 
against intracellular antigen (GAD-AB).
 In a recent study on 7 ICU patients with NMDAR-AB 
 [17] , with an age range from 19 to 31, the outcome was 
favorable in all of them. Another 6 ICU patients with 
NMDAR-AB and encephalitis, with an age range from 20 
to 41, were reported in a recent cohort study  [18] . Half of 
them had a slow but good recovery, 2 were left with severe 
neurological deficits and 1, the oldest of the cohort, suc-
cumbed to pneumonia 6 months after onset. Thus the 
outcome remains variable and unpredictable, even if the 
type of AB and the age range are comparable. 
 It is of note that most patients survived and 62% (8/13) 
with good-to-excellent neurological and cognitive out-
come, although recovery in some cases took up to two 
years. Outcome was independent of the duration of sta-
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tus, i.e. even with AB-SE of several months, there was a 
good chance for full or almost full recovery. This is exem-
plified by patients 5 and 7, who were in SE for 3 and 4 
months, respectively, but eventually recovered almost 
completely. This is an important observation, given the 
recurrent discussions with ICU staff that arise regarding 
how long these patients should remain on life support and 
whether they will recover. 
 Despite the recent sharp increase in the description of 
autoimmune epilepsy and AB-SE in the literature, there 
is still no established algorithm of treatment strategy. 
Prospective multicenter studies are needed to determine 
optimal treatment, and whether early and aggressive im-
munomodulatory therapy prevents fatal outcome and/or 
shortens significantly the ICU stay. An additional point 
to consider is also that early treatment requires fast labo-
ratory confirmation of relevant AB in high titers. Fur-
thermore, increased awareness of this often reversible 
condition (SE of unclear origin, with a history of neu-
ropsychiatric or infectious symptoms) is mandatory to 
shorten the delay to proper diagnosis and treatment.
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